Raymond Hautamaki
Internal Medicine · Sarasota, FLNPI 1174685499
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 108 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 32 manufacturers, the largest accounting for just 10.2% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $890 and has fallen 94.3% since, to $51 in 2025.
Across 108 payments — averaging $17.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$193
- Johnson & Johnson$192
- Amgen$183
- Pfizer$138
- Philips North America LLC$121
- Takeda Pharmaceuticals U.S.A., Inc.$109
- plus $957 from 26 others
What the payments were for
- Food & beverage$1,894100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XARELTO$111
How this compares
$1,894 in reported general payments places this provider in the 80th percentile of 8,530 internal medicine providers in Florida.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 38 | $39,631 |
| EliquisApixaban | 23 | $22,652 |
| FarxigaDapagliflozin Propanediol | 14 | $11,003 |
| ValacyclovirValacyclovir Hcl | 15 | $691 |
| Rosuvastatin Calcium | 28 | $535 |
| Gabapentin | 14 | $504 |
| Ezetimibe | 14 | $471 |
| Solifenacin Succinate | 12 | $469 |
| Pantoprazole Sodium | 24 | $430 |
| Levothyroxine Sodium | 32 | $418 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 11 | $383 |
| Atorvastatin Calcium | 29 | $339 |
| Celecoxib | 14 | $264 |
| Doxycycline Hyclate | 13 | $245 |
| Losartan Potassium | 22 | $243 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro | $37 | $39,63138 claims |
| PfizerEliquis | $138 | $22,65223 claims |
| AstraZenecaFarxiga | $19 | $11,00314 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 8,530 internal medicine providers in Florida.
Other internal medicine in Sarasota
- Kaitlin LimaSarasota$91K
- Haytham ElgammalMiami$2.2M
- Keith RubinFort Lauderdale$2M
- Michael SensionFort Lauderdale$1M
- Quang NguyenOcala$434K
- Luis Correa LunaSanford$412K
- Michael OleksykFort Myers$365K
- Andrew KuykendallTampa$322K
- Howard FederoffCoconut Grove$302K
- Bianka EperjesiovaGainesville$260K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.